CD34+ Enriched Transplant

A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myelodysplastic Syndrome

What's the purpose of the trial?

This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat a blood malignancy (cancer) or blood disorder. The CliniMACS system will be used to remove immune T-cells from the transplant donor's blood. Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or reducing the severity of GVHD.
Trial status

Not currently accepting

Phase
Phase 2
Enrollment
50
Last Updated
1 month ago
Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Allogeneic Stem Cell Transplant is a type of stem cell transplant that utilizes a donor's pre-collected stem cells to rescue the bone marrow from the toxic effects of very high dose chemotherapy.
  • Busulfan is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body, and may be used in the treatment of many different cancers.
  • Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
  • Melphalan is a chemotherapy medication used in the treatment of different cancers.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not currently accepting

CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan + Melphalan + Fludarabine

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.